Nanomedicine Market- By Modality (Treatment and Diagnosis), By Application (Drug Delivery, Diagnostic Imaging, Vaccines, Regenerative Medicine, Implants, and Others), By Indication (Oncologicy, Infectious Diseases, Cardiovascular, Orthopedic Disorders, Neurology, Urolog, Ophthalmological Diseases, Immunological Diseases, and Others), and By Region - Global Opportunity Analysis and Industry Forecast, 2020 – 2030

Nanomedicine Market valued USD 138.9 billion in 2020 and it is expected to reach USD 455.3 billion by 2030 with the CAGR of 12.6% during the forecast period. Nanomedicine is an application of nanotechnology which is used in diagnosis, treatment, monitoring, and control of biological systems. Nanomedicine uses nanoscale manipulation of medicine to improve medicine delivery. Nanomedicine is used for the treatment against various diseases related to oncology, cardiology, neurology, and among others. Nanomedicine uses nano sized tools for the diagnosis, prevention, treatment, and monitoring of diseases. It includes three nanotechnology areas of imaging agents, diagnosis, and drug delivery with nanoparticles in the 1–1,000 nm range, polymer therapeutics, and biochips.

Market Segmentation:

Nanomedicine market is segmented on the basis of modality, application, indication, and by region. Based on modality market bifurcated into treatments and diagnosis. Based on application market is characterized into drug delivery, diagnostic imaging, vaccines, regenerative medicine, implants, and others. Based on indication market is classified into infectious diseases, oncology, cardiovascular, urology, neurology, immunological diseases, and others. Based on region market is segmented into North America, Europe, Asia Pacific, and RoW.

Market Dynamics and Factors:

Some of the major driving factors include its application in various therapeutic areas, increasing in R&D studies about nanorobots, and significant investments in clinical trials by the government as well as private sectors. In addition to this, nanomedicine offers changes in treatment and diagnosing of cancer. Such as minimal infusion of treatment in body and drug testing. Moreover, emerging technologies along with increase in adoption of nanomedicine, rise in government support & funding, growth in need for therapies with low side effects, and cost-effectiveness of therapies, drug delivery, are some of the factors positively impacting on the market growth in near future. For instance, such as drug delivery testing in laboratory diagnostics help in complete menu of EMIT (enzyme multiplied immunoassay technique) that helps in routine check of drug reactions, protein in urine and serum. Furthermore, rise in out-licensing of nanodrugs and growth of healthcare facilities in developing countries are potential opportunities for the growth of nanomedicine market. However, long approval process of regulatory and risks associated with nanomedicine are restraining the market growth.

Geographic Analysis:

Geographically, North America is dominating market owing to increased number of cancer patients, increase in geriatric population and government support for licensing of medicine. Asia-pacific is expected to emerge as the fastest growing region due to increase in cases of cancer cases along with geriatric population, improvement of healthcare infrastructure and services in rural area.

Competitive Scenario:

Some of the major players operating in the market are Sanofi SA, Pfizer Inc, Celgence Corporation, Luminex Corporation, Johnson and Johnson, GE Healthcare, Siemens Healthcare Inc, Teva Pharmaceutical Industries Ltd, Ablynx NV, Abraxis Biosciences, and Pfizer Inc

Nanomedicine Market Report Scope